One Day MD | Evidence-Based Wellness

2026 Evidence & Treatment Guide GLP-1 treatment has moved beyond the original Ozempic vs. Wegovy conversation. In 2026, people considering medical treatment for obesity may encounter weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide, and the new oral GLP-1 medicine Foundayo (orforglipron) by Eli Lilly . The important question is no longer simply "Which GLP-1 is strongest?" A better approach is to compare the medicines by indication, clinical evidence, route, tolerability, cardiovascular or sleep-apnea considerations, cost, access, long-term maintenance, and the person's broader health goals. Updated: September 27, 2026   |   Regulatory reference: U.S. FDA labeling   |   Scope: Adult obesity treatment unless otherwise stated Important medical note: This page is educational information, not a diagnosis or personal treatm...

GLP-1 medications can produce substantial weight loss, but the scale does not tell you whether that weight came from fat, lean tissue, or both. As semaglutide, tirzepatide and other incretin-based therapies become increasingly important in obesity treatment, a more useful question is emerging: how can weight be lost while preserving muscle, physical function and long-term health? Evidence review updated: September 28, 2026  |  Topic: GLP-1 medications, muscle loss, lean mass, metabolism and weight regain The evidence in one paragraph: Substantial weight loss from semaglutide, tirzepatide and other incretin-based therapies can include a measurable reduction in lean mass. However, a 2026 systematic review and meta-analysis found that the proportion of total weight lost as lean mass was broadly comparable with intensive lifestyle-based weight loss, rather than showing that incretin drugs uniquely cause muscle loss. The same analysis found the most favorable lean-ma...